12:17 PM EST, 01/08/2025 (MT Newswires) -- Collegium Pharmaceutical ( COLL ) shares rose by nearly 13% in recent trading on Wednesday after the company provided 2025 guidance.

Collegium said it expects 2025 product revenue of between $735 million to $750 million. Analysts polled by FactSet expect $739.9 million.

Jornay PM, an attention-deficit/hyperactivity disorder drug, is positioned to be the lead growth driver, with expected net revenue of more than $135 million in 2025, Collegium said.

Price: 32.82, Change: +3.68, Percent Change: +12.63